Endoscopic screening has been proposed for patients with symptoms of gastro-oesophageal reflux disease (GERD) in the hope of reducing mortality from oesophageal adenocarcinoma. Assessing the net benefits of such a strategy requires a precise understanding of the cancer risk in the screened population.
ABSTRACT Background
Endoscopic screening has been proposed for patients with symptoms of gastro-oesophageal reflux disease (GERD) in the hope of reducing mortality from oesophageal adenocarcinoma. Assessing the net benefits of such a strategy requires a precise understanding of the cancer risk in the screened population.
Aim
To estimate precisely the association between symptoms of GERD and oesophageal adenocarcinoma.
Methods
Systematic review and meta-analysis of population-based studies with strict ascertainment of exposure and outcomes.
Results
Five eligible studies were identified. At least weekly symptoms of GERD increased the odds of oesophageal adenocarcinoma fivefold (odds ratio = 4.92; 95% confidence interval = 3.90, 6.22) , and daily symptoms increased the odds sevenfold (random effects summary odds ratio = 7.40, 95% confidence interval = 4.94, 11.1), each compared with individuals without symptoms or less frequent symptoms. Duration of symptoms was also associated with oesophageal adenocarcinoma, but with very heterogeneous results, and unclear thresholds.
Conclusions
Frequent GERD symptoms are strongly associated with oesophageal adenocarcinoma. These results should be useful in developing epidemiological models of the development of oesophageal adenocarcinoma, and in models of interventions aimed at reducing mortality from this cancer. Titles were reviewed by a single author (JBT) and abstracts of interest were reviewed independently by two authors (JBT and JHR). To be eligible, studies had to examine cancer diagnosis and include data regarding gastro-oesophageal reflux disease. Cases and controls were required to be obtained through population-based sampling, and histological confirmation of oesophageal adenocarcinoma was required. Gastro-oesophageal reflux symptoms were required to be assessed either by a questionnaire or interview; studies relying on assessment of gastro-oesophageal reflux disease by medical chart review, administrative diagnosis codes, or prescription databases were excluded. Symptoms of gastro-oesophageal reflux disease were defined as retrosternal burning discomfort and ⁄ or effortless regurgitation. Relevant manuscripts were cross-referenced to identify additional potential studies.
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Although each study matched controls to cases based on at least age, crude odds ratios from each study were obtained using an unconditional analysis. We estimated the odds ratios for individuals with weekly symptoms of gastro-oesophageal reflux disease vs. those without symptoms or those with symptoms less than weekly and also for individuals with daily symptoms vs. those without symptoms or those with symptoms less than weekly. For meta-analysis of duration of symptoms, effects were examined for duration greater than 20 years, and for duration less than 10-15 years. One study did not present results for duration. 7 One presented data for categories of 20-30 years and greater than 30 years, not permitting the ability to use the adjusted effects for both categories combined; for that study, we used the crude data for that stratum. 4 Meta-analysis was performed using MIX v.2.0 software (Leon Bax, Kitasato University, Tokyo, Japan). 12, 13 Fixed-effects models were tested for heterogeneity, and exclusion sensitivity analysis was performed to try to explain heterogeneous findings. As the subjects in the identified studies were overwhelmingly classified as of white race and as no estimates of the risk of gastro-oesophageal reflux disease were provided stratified by race or ethnicity, the results only reflect a white, non-Hispanic population.
RESULTS

Systematic review
Our systematic review identified 13 392 citations; titles and abstracts were manually evaluated for relevancy. Of these, we found five studies eligible for inclusion ( Figure 1 and Table 1) . [3] [4] [5] [6] [7] Additional potential studies were excluded because gastro-oesophageal reflux disease M Me et ta a--a an na al ly ys si is s: : o od dd ds s o of f o oe es so op ph ha ag ge ea al l a ad de en no oc ca ar rc ci in no om ma a i in n G GE ER RD D Aliment Pharmacol Ther 2010; 32: 1222-1227
was assessed by chart review, 14, 15 or because gastrooesophageal reflux disease was considered present if subjects consumed antacids regardless of specific symptoms. 16 One study was excluded because the definition of gastro-oesophageal reflux disease did not include regurgitation and the frequency of symptoms was not reported. 17 One additional potential study had been only presented in abstract; 18 attempts to obtain relevant data through personal communication with the authors were unsuccessful. Each study had a retrospective case-control design. In each study design, to avoid reverse causality, symptoms were excluded for a time period (1-10 years) preceding the diagnosis of cancer or the match date. Three studies estimated the association of gastro-oesophageal reflux symptoms with other relevant cancers (such as oesophageal squamous cell carcinoma), finding no relationship with gastro-oesophageal reflux symptoms, thereby making recall bias an unlikely explanation of the relationship between gastro-oesophageal reflux symptoms and oesophageal adenocarcinoma. [3] [4] [5] In all but one study, the prevalence of weekly gastro-oesophageal reflux symptoms in the subjects with oesophageal adenocarcinoma was less than 50% (Table 1) .
Meta-analysis of symptom frequency
The random effects summary odds ratio for oesophageal adenocarcinoma of weekly gastro-oesophageal reflux symptoms vs. less frequent or no symptoms was 4.92 [95% confidence interval (CI) = 3.90, 6.22], and exhibited moderate heterogeneity (Cochrane's Q P = 0.04; Inconsistency Index, I 2 = 60%) (Figure 2 ). Removing the outlier study by Lagergren et al. 3 resolved this heterogeneity (fixed effects odds ratio = 4.57; 95% CI = 3.89, 5.36; Cochrane's Q P = 0.36, I 2 = 6%). The random effects summary odds ratio for oesophageal adenocarcinoma of daily gastro-oesophageal reflux symptoms vs. symptoms less than weekly or no symptoms was 7.40 (95% CI = 4.94, 11.1), and also exhibited moderate heterogeneity (Cochrane's Q P = 0.01; I 2 = 71%). Removing the Lagergren study partially resolved the heterogeneity (fixed effects odds ratio = 6.20; 95% CI = 4.95, 7.78; Cochrane's Q P = 0.17; I 2 = 40%). In the one study where data were available, the association between weekly gastro-oesophageal reflux symptoms and oesophageal adenocarcinoma may have been slightly weaker in women than in men (men: odds ratio = 4.3, 95% Meta-analysis of symptom duration One study did not collect data on symptom duration. 7 The results from the other four studies are summarized in Table 2 . For symptoms of at least 20 years, the random effects summary odds ratio was 5.41 (95% CI = 2.45, 11.9), but with very heterogeneous results (Cochranes Q P < 0.01, I 2 = 89%). Excluding any one study failed to resolve the heterogeneity. For symptoms of shorter duration (less than 10-15 years, depending on the study), the random effects summary odds ratio was 3.05 (95% CI = 1.53, 6.08). Once again, these results were very heterogeneous (Cochranes Q P < 0.01, I 2 = 84%), and excluding any one study failed to resolve the heterogeneity.
DISCUSSION
We conducted a systematic review and meta-analysis of the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux disease. The first high-quality study demonstrating the association of gastrooesophageal reflux symptoms with oesophageal adenocarcinoma was published in 1999. 3 Since then, four more population-based studies have been published. Although the associations in those studies have been weaker than that described in the initial report, each study has demonstrated strong associations with such symptoms, and each with a positive dose-response relation in terms of frequency of gastro-oesophageal reflux symptoms. Overall, we found that individuals with weekly symptoms have an approximate fivefold increase in the odds of developing oesophageal adenocarcinoma, and those with daily symptoms have an approximate sevenfold increase in the odds of the cancer compared with individuals with symptoms less than weekly or no symptoms. However, most patients with oesophageal adenocarcinoma denied ever having symptoms of gastro-oesophageal reflux at least weekly. Each study found a strong relationship between oesophageal adenocarcinoma and reflux symptoms of at least 20 years, but the results from the studies were very heterogeneous, with odds ratios ranging from 2.26 to 16.4. Two of the studies found little threshold effect comparing the odds ratios for symptoms less than 10-15 years' duration and symptoms of greater than 20 years' duration, both vs. no symptoms. Multiple guidelines describe a strong association between symptom duration and the risk of Barrett's oesophagus, 19, 20 but the association between duration and cancer is not as strong as the data for symptom frequency, and it remains unclear what duration of symptoms would be relevant for cancer screening purposes. Additional population-based studies examining the effect of symptom duration and its interaction with symptom frequency for oesophageal adenocarcinoma are needed. CI, confidence interval; GERD, gastro-oesophageal reflux disease; OR, odds ratio.
* Odds ratio is a crude estimate.
M Me et ta a--a an na al ly ys si is s: : o od dd ds s o of f o oe es so op ph ha ag ge ea al l a ad de en no oc ca ar rc ci in no om ma a i in n G GE ER RD D Aliment Pharmacol Ther 2010; 32: 1222-1227
Although gastro-oesophageal reflux symptoms are clearly strongly associated with the odds of developing oesophageal adenocarcinoma, the absolute risk of that cancer in the population is quite low. The very strong relative risk associated with frequent gastro-oesophageal reflux symptoms should not be confused with the absolute risk of cancer in individuals with these symptoms, which may be quite small, and is not directly addressed in the current study. Nonetheless, these precise estimates of the relative risk of oesophageal adenocarcinoma should prove useful in epidemiological models of the development of oesophageal adenocarcinoma, and in models of interventions to reduce mortality from this type of cancer.
Our study was limited by the available published literature. In particular, all five studies were primarily or entirely conducted in white, non-Hispanic populations therefore the magnitude of the association may differ in other populations. However, given the low baseline incidence of oesophageal adenocarcinoma in some of those other populations (e.g. Asian and African), the association with reflux symptoms in those populations would likely need to be much stronger than among whites for the symptoms to be relevant to the health of individuals of minority populations. Moreover, we were not able to assess the possibility of interactions with other risk factors, such as age, gender, obesity, or tobacco use. For instance, although all of the studies adjusted the effect estimates of gastro-oesophageal reflux symptoms for obesity, Whiteman, et al. further demonstrated a synergistic relationship between reflux and obesity for oesophageal adenocarcinoma. 7 Obesity might promote oesophageal adenocarcinoma independent of a mechanical effect promoting reflux, such as via circulating adipokines. [21] [22] [23] [24] [25] Major strengths of the study include each underlying study was a very high quality study, utilizing populationbased sampling and strict ascertainment of both exposures and outcomes, and most adjusting for multiple potential confounders. The reason for the stronger relationship between gastro-oesophageal reflux symptoms and oesophageal adenocarcinoma in the first published study than in later studies is not clear. It may due to differences in the underlying population (Swedish) vs. the other studies (American, Australian and Irish), the questionnaires ascertaining gastro-oesophageal reflux symptoms, or the particular definitions used for oesophageal vs. cardia or junctional adenocarcinomas. Moreover, the Swedish study was the only one to adjust for diet and physical activity.
In summary, we have conducted a systematic review and meta-analysis demonstrating a strong, dose-dependent relationship between frequency of symptoms of gastrooesophageal reflux and oesophageal adenocarcinoma.
